{"product_id":"nipro-bcg-matrix","title":"Nipro Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Strategic Snapshot for Nipro\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNipro's Boston Consulting Group (BCG) Matrix preview shows where major product lines-renal care (including dialysis), infusion therapy and cardiovascular devices, and pharmaceutical packaging-likely sit among Stars, Cash Cows, Question Marks, and Dogs, based on market share and growth. This concise overview highlights strategic priorities-invest, harvest, divest, or investigate-while the full BCG Matrix delivers quadrant-level data, visual maps, and actionable recommendations to guide resource allocation. Purchase the complete report for editable Word and Excel files with deeper analysis and ready-to-apply strategic steps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRenal Care Dialysis Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro holds a top global share in dialysis machines, serving a market growing ~6.5% CAGR to 2025 as CKD (chronic kidney disease) prevalence rose to 9.1% globally in 2024 (Global Burden of Disease data).\u003c\/p\u003e\n\u003cp\u003eThe company reinvests large capex-about ¥40-50 billion (FY2024 guidance range)-into high-tech dialysis units with digital remote monitoring and AI dialysis-control features piloted in Japan and EU sites.\u003c\/p\u003e\n\u003cp\u003eAs hospitals modernize, dialysis equipment is Nipro's Medical Device growth engine, projected to drive ~30% of segment revenue by FY2025 and sustain mid-single-digit organic growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Infusion Therapy Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift to smart infusion pumps and safety-engineered needles has made Nipro a market leader in high-growth infusion: 2024 sales for infusion systems rose ~18% y\/y to ¥42.3bn (≈ $290m), capturing an estimated 34% share in hospital-grade smart pumps in Japan and APAC.\u003c\/p\u003e\n\u003cp\u003eThese Stars need ongoing R\u0026amp;D-Nipro spent ¥6.1bn on R\u0026amp;D in FY2024-to comply with evolving U.S. and EU safety and IEC\/ISO interoperability standards.\u003c\/p\u003e\n\u003cp\u003eStrong demand from hospital networks keeps them a top growth priority: recurring consumables lift attach rates to 1.6 devices per bed in large hospitals, supporting double-digit revenue growth forecasts through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVascular Intervention Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's push into vascular intervention devices-stents and catheters-targets a market growing ~6.8% CAGR to 2028, driven by aging populations; Japan's ≥65 cohort is 29% in 2025, boosting domestic demand. \u003c\/p\u003e\n\u003cp\u003eThese devices gained traction in emerging markets, where Nipro grew vascular revenue ~22% YoY in FY2024 and took share from legacy firms in Southeast Asia and Latin America. \u003c\/p\u003e\n\u003cp\u003eHigh technical expertise and regulatory know‑how create a moat, yet marketing, FDA\/PMDA trials and postmarket studies drove R\u0026amp;D + SG\u0026amp;A spend to ~14% of sales in FY2024, pressuring free cash flow. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Pharmaceutical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs many biologic patents expire through 2025, Nipro's biosimilar push has entered high-growth phase, with company reporting a 2024 Japan\/Asia biosimilar revenue slice growing ~40% YoY to an estimated ¥18-22 billion (approx $130-160M) and expanding market share in oncology\/autoimmune segments.\u003c\/p\u003e\n\u003cp\u003eDevelopment needs massive upfront spend-facility capex often ¥10-30 billion ($70-210M) per product and regulatory costs ~¥1-3 billion-yet successful launches can yield 30-50% gross margins and leadership in higher-price biologic categories.\u003c\/p\u003e\n\u003cp\u003eThese biosimilars are pivotal for Nipro's strategic shift from generics to high-value biopharma, enabling ASP (average selling price) capture, longer product lifecycles, and higher EBITDA contribution versus small-molecule generics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue growth ~40% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated biosimilar revenue ¥18-22B (2024)\u003c\/li\u003e\n\u003cli\u003eCapex per product ¥10-30B, regulatory ¥1-3B\u003c\/li\u003e\n\u003cli\u003eTarget gross margins 30-50%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEco-friendly Pharmaceutical Glass Packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEco-friendly Pharmaceutical Glass Packaging sits in the Stars quadrant: global demand for recyclable tubing and vials grew ~12% YoY to $4.8B in 2024, and Nipro holds a major share (~18%) in 2025 thanks to premium quality and regulatory compliance.\u003c\/p\u003e\n\u003cp\u003eNipro's carbon-neutral glass lines (launched 2023-2024) secured multi-year contracts with Pfizer and Roche, adding €220M in committed revenue through 2027; capacity must scale 40% by 2026 to meet orders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCategory growth ~12% YoY to $4.8B (2024)\u003c\/li\u003e\n\u003cli\u003eNipro market share ~18% (2025)\u003c\/li\u003e\n\u003cli\u003e€220M secured contracts to 2027\u003c\/li\u003e\n\u003cli\u003ePlanned capacity +40% by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro's core businesses fuel double‑digit growth; biosimilars \u0026amp; glass scale to 2026\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's Stars (dialysis, infusion, vascular devices, biosimilars, eco glass) drive double‑digit growth: FY2024 sales up ~18-40% in key areas, R\u0026amp;D ¥6.1bn, capex ¥40-50bn, biosimilar rev ¥18-22bn, glass share ~18% with €220M contracts; sustain investment to protect regulatory moat and scale capacity by +40% to 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis\/Infusion\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eSales growth ~18%, market share top global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eRev ¥18-22bn, growth ~40% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlass packaging\u003c\/td\u003e\n\u003ctd\u003e2024\/25\u003c\/td\u003e\n\u003ctd\u003eMarket $4.8B, Nipro share ~18%, €220M contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/Capex\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D ¥6.1bn, capex ¥40-50bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Nipro's portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Nipro BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Hemodialyzers and Blood Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard hemodialyzers and blood lines generate roughly 55-65% of Nipro's dialysis revenue, holding a stable global market share near 18% in 2024 in the mature dialysis consumables market.\u003c\/p\u003e\n\u003cp\u003eEstablished tech and scale drive gross margins around 42-46% and operating cash flow that funded ~40% of Nipro's 2024 R\u0026amp;D spend (¥8.2bn), supporting higher-risk medtech projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Oral Solid Dosage Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro's generic oral solid dosage drugs sit in a mature Japanese market worth about JPY 2.2 trillion (2024), with steady volume and predictable demand; unit sales grew ~1.5% YoY in 2024, supporting margin stability. \u003c\/p\u003e\n\u003cp\u003eLow incremental marketing and capex needs keep EBITDA conversion high-Nipro reported consolidated cash flow from operations of JPY 34.8 billion in FY2024-so these products reliably service corporate debt. \u003c\/p\u003e\n\u003cp\u003eEstablished distribution via Japan's hospital and pharmacy networks captures \u0026gt;60% of domestic shares for key SKUs, making this portfolio a stable cash cow funding R\u0026amp;D and higher-growth units. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Pharmaceutical Glass Vials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStandard pharmaceutical glass vials are a cash cow for Nipro, where it leads global production with about 1.2 billion units in 2024 and ~18% market share in primary glass vials for injectables (source: company filings, FY2024).\u003c\/p\u003e\n\u003cp\u003eThese mature products need low R\u0026amp;D, so Nipro PharmaPackaging converts steady vaccine and injectable demand into high margins-reported operating margin ~22% in FY2024-letting the firm consistently 'milk' cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Surgical and Nursing Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBasic surgical and nursing disposables such as syringes and needles generate steady, high-volume sales for Nipro with market share estimates around 25-35% in key markets, but face low market growth under 3% annually as procurement shifts to cost-competitive sourcing.\u003c\/p\u003e\n\u003cp\u003eThese commodity items require minimal promotion, deliver predictable gross margins (mid-20s percent range in 2024), and function as cash cows funding admin costs and supporting dividend capacity-Nipro reported ¥23.5 billion operating cash flow in FY2024, partly driven by these lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh share, low growth: ~25-35% share; \u0026lt;3% market CAGR\u003c\/li\u003e\n\u003cli\u003eStable margins: mid-20s% gross margin (2024)\u003c\/li\u003e\n\u003cli\u003ePredictable cash: contributed to ¥23.5B operating cash flow (FY2024)\u003c\/li\u003e\n\u003cli\u003eLow promo cost, supports dividends and admin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services (CDMO)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNipro's Contract Development and Manufacturing Organization (CDMO) is a cash cow: in 2024 it ran at ~70% capacity utilization and contributed roughly ¥35-45 billion in annual revenue, delivering mid‑teens EBITDA margins-steady cash flow with low incremental capex because it uses existing plants for third‑party pharmaceutical brands.\u003c\/p\u003e\n\u003cp\u003eThe CDMO stabilizes group cash generation independent of Nipro's branded drug launches; in 2024 external manufacturing made up about 30% of consolidated operating profit, smoothing quarterly volatility and funding R\u0026amp;D and capex for growth areas.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e70% capacity use (2024)\u003c\/li\u003e\n\u003cli\u003e¥35-45bn revenue (2024 est.)\u003c\/li\u003e\n\u003cli\u003e~15% EBITDA margin\u003c\/li\u003e\n\u003cli\u003e~30% of operating profit\u003c\/li\u003e\n\u003cli\u003eLow incremental capex per new contract\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro's cash cows drive ¥34.8bn CFO: strong margins, market shares across units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's cash cows (dialysis consumables, pharma packaging, generics, disposables, CDMO) delivered stable revenue and high cash conversion in FY2024: dialysis 55-65% of dialysis revenue, 18% market share; pharma vials 1.2bn units, 18% share; CDMO ¥35-45bn revenue, ~15% EBITDA; consolidated CFO ¥34.8bn; operating cash flow from major lines ≈¥23.5bn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 KPI\u003c\/th\u003e\n\u003cth\u003eMargin\/Share\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis consumables\u003c\/td\u003e\n\u003ctd\u003e55-65% dialysis rev\u003c\/td\u003e\n\u003ctd\u003e18% global, 42-46% GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma vials\u003c\/td\u003e\n\u003ctd\u003e1.2bn units\u003c\/td\u003e\n\u003ctd\u003e18% global, 22% OM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\u003c\/td\u003e\n\u003ctd\u003e¥35-45bn rev\u003c\/td\u003e\n\u003ctd\u003e~15% EBITDA, 70% util\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eNipro BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Nipro BCG Matrix report you'll receive after purchase-no watermarks, no placeholders, just the fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Diagnostic Imaging Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy diagnostic imaging equipment at Nipro holds low market share in a stagnant segment, facing stiff competition from Siemens Healthineers and GE Healthcare; global MRI\/CT sales grew ~2% in 2024 while Nipro's imaging revenue fell ~8% year-on-year to an estimated ¥4.2bn (2024 YTD), showing weak demand.\u003c\/p\u003e\n\u003cp\u003eThese older systems incur high service and parts costs-field service can exceed 15% of unit price annually-cutting margins versus renal care where EBIT margins exceed 18% in 2024; imaging margins were roughly 4% last year.\u003c\/p\u003e\n\u003cp\u003eGiven low growth, high upkeep, and capital intensity, imaging is a primary divestiture candidate as Nipro reallocates capital toward dialysis and specialized devices where projected CAGR is ~6% through 2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Margin Generic Injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain basic generic injectable drugs have become commoditized, squeezing gross margins to single digits; industry data show 2024 median gross margin for commodity injectables ~8%, while Nipro's comparable lines report break-even or small losses and under 5% market share versus local players.\u003c\/p\u003e\n\u003cp\u003eThese SKUs tie up working capital and 18-22% of manufacturing capacity, diverting management focus from higher-margin biosimilars where Nipro targets 20-30% EBITDA; without a clear route to leadership, the company plans to minimize or phase out these lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-Scale Home Healthcare Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSmall-scale home healthcare kits for non-chronic use sit in Nipro's Dogs quadrant: \u003cbr\u003e2025 revenue under ¥2.5bn (~US$17.5m) and \u0026lt;3% company sales, market share \u0026lt;2% vs consumer brands; segment growth ~2% CAGR (2023-25).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Laboratory Glassware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional Laboratory Glassware sits in Nipro's BCG matrix as a Dog: non-pharmaceutical lab glassware is a stagnant market (global labware growth ~1-2% CAGR 2020-25) where Nipro's share is under 1% versus specialty suppliers, yielding low margins and negligible EBITDA contribution in 2024.\u003c\/p\u003e\n\u003cp\u003eThe unit shows limited upside compared with Nipro's pharma packaging (2024 packaging revenue ~JPY 220bn), faces recurring budget cuts, and is slated for consolidation or divestiture.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth ~1-2% CAGR 2020-25\u003c\/li\u003e\n\u003cli\u003eNipro share \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003eMinimal EBITDA; not material to consolidated results\u003c\/li\u003e\n\u003cli\u003eFrequent budget cuts; consolidation likely\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Respiratory Therapy Accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder respiratory accessories at Nipro, superseded by modern ventilation tech, sit in a declining segment with under 2% market share and year-on-year revenue drop of ~18% in 2024, attracting no new capex and minimal orders.\u003c\/p\u003e\n\u003cp\u003eThese catalog items are maintained for legacy customers but classified as dogs in the BCG matrix, targeted for phased exit to cut SKU complexity and reduce annual carrying costs (estimated $0.9m in 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeclining segment: \u0026lt;1-2% market share\u003c\/li\u003e\n\u003cli\u003eRevenue trend: -18% YoY (2023→2024)\u003c\/li\u003e\n\u003cli\u003eCarrying cost: ~$0.9m in 2024\u003c\/li\u003e\n\u003cli\u003eAction: managed for phased exit, no new investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompany to divest low‑margin \"Dogs\" (¥6.5bn, ~3% margin) to fund dialysis \u0026amp; biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy imaging, commodity injectables, small home kits, lab glassware, and old respiratory accessories-combined 2024 revenue ~¥6.5bn (~US$45m), avg margin ~3%, market share \u0026lt;3% per line, CAGR 2020-25 ~0-2%; targeted for divestiture\/consolidation to free capex for dialysis and biosimilars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev (¥bn)\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eCAGR 20-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy imaging\u003c\/td\u003e\n\u003ctd\u003e4.2\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e4%\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectables\u003c\/td\u003e\n\u003ctd\u003e0.6\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0-9%\u003c\/td\u003e\n\u003ctd\u003e0-1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome kits\u003c\/td\u003e\n\u003ctd\u003e2.5\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab glassware\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003eNegligible\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory acc.\u003c\/td\u003e\n\u003ctd\u003e0.2\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e~3%\u003c\/td\u003e\n\u003ctd\u003e-18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Remote Patient Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro is investing in remote patient monitoring (RPM) for renal care, a high-growth market projected at CAGR ~18% to reach $6.5B by 2028 (global RPM market); Nipro currently holds low share in renal RPM. \u003c\/p\u003e\n\u003cp\u003eShift to home dialysis could drive device+software sales-home dialysis use rose ~22% in US from 2018-2023-yet RPM needs heavy software and cybersecurity spend (est. 15-25% of project costs). \u003c\/p\u003e\n\u003cp\u003eSuccess hinges on convincing providers to adopt Nipro's closed digital ecosystem; commercial adoption risk is high without interoperability and payer reimbursement evidence. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy Packaging Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cell and gene therapy packaging market is growing ~25% CAGR to reach ~$12B by 2028, and Nipro currently holds minimal share as an emergent player in 2025.\u003c\/p\u003e\n\u003cp\u003eThese products need specialized materials plus ultra-cold chain (-80°C) compatibility, driving upfront R\u0026amp;D and CAPEX-industry median upfront spend ~10-15% of product revenue; Nipro must invest similarly.\u003c\/p\u003e\n\u003cp\u003eIf Nipro captures early contracts and scales, this unit could become a Star with high margins and double-digit growth; if not, it risks becoming a cash-burning Question Mark. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional Oncology Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's Interventional Oncology entry-specialized ablation needles-targets a global tumor ablation market projected to reach $2.1B by 2028 (CAGR ~6.8%), yet Nipro holds \u0026lt;2% share in oncology devices as of 2025.\u003c\/p\u003e\n\u003cp\u003eMarketing hinges on clinical trials: a 2024 pilot showed 72% local tumor control at 12 months; broader RCTs planned for 2025-26 to build trust versus established firms like Medtronic and Boston Scientific.\u003c\/p\u003e\n\u003cp\u003eThese products are cash-intensive: R\u0026amp;D and trial costs estimated ¥3-5bn JPY ($21-35M) over 24 months; rapid scaling to \u0026gt;10% segment share in 3 years is needed to avoid low-margin Dog status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArtificial Intelligence Diagnostic Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNipro's AI diagnostic software sits as a Question Mark: kidney-disease AI SaaS is a high-growth field (CAGR ~41% for AI healthcare diagnostics, 2024-30) where Nipro is a newcomer with low current revenue but strong strategic upside if bundled with its dialysis hardware.\u003c\/p\u003e\n\u003cp\u003eGaining share needs heavy spend-estimated $30-70M for data science, clinical trials, and regulatory approvals per product-and fast adoption to turn into a Star; rivals include Viz.ai and Caption Health with published clinical validations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: ~41% CAGR in AI healthcare diagnostics (2024-30)\u003c\/li\u003e\n\u003cli\u003eLow current returns: SaaS early-stage revenues\u003c\/li\u003e\n\u003cli\u003eInvestment need: $30-70M per product for data\/regulatory\u003c\/li\u003e\n\u003cli\u003eStrategy: bundle AI with Nipro dialysis hardware to capture value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Geographic Market Expansions (Africa\/LATAM)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNipro's Question Marks: aggressive entry into Africa and LATAM with full medical portfolio where current share \u0026lt;5% but CAGR demand \u0026gt;8% (IMS Health 2024); high upside if share reaches 10-15% by 2028. \u003c\/p\u003e\n\u003cp\u003eThese units need heavy capex for local manufacturing, distribution, and regulatory compliance-estimated $40-70M per region in first 3 years to be competitive against B. Braun and Fresenius. \u003c\/p\u003e\n\u003cp\u003eOutcome uncertain; success is crucial for Nipro's global revenue mix-could lift group sales by 6-10% by 2030 if execution hits targets. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCurrent share \u0026lt;5%, market growth \u0026gt;8% CAGR\u003c\/li\u003e\n\u003cli\u003eCapex $40-70M\/region (first 3 years)\u003c\/li\u003e\n\u003cli\u003eTarget share 10-15% by 2028\u003c\/li\u003e\n\u003cli\u003ePotential +6-10% group sales by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro's high-risk, high-reward bets: $30-70M AI, ¥3-5bn oncology-could add 6-10% sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's Question Marks-renal RPM, cell\/gene packaging, oncology ablation, AI diagnostics, Africa\/LATAM entry-are high-growth but low-share; required investments range $30-70M per AI\/product, ¥3-5bn JPY ($21-35M) for oncology trials, $40-70M per region capex; success could add 6-10% group sales by 2030, failure risks cash-burning Dogs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCurrent share\u003c\/th\u003e\n\u003cth\u003eInvest\u003c\/th\u003e\n\u003cth\u003eUpside\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPM\u003c\/td\u003e\n\u003ctd\u003e18%CAGR\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e15-25% proj cost\u003c\/td\u003e\n\u003ctd\u003ehome dialysis shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI\u003c\/td\u003e\n\u003ctd\u003e41%CAGR\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003ctd\u003e$30-70M\u003c\/td\u003e\n\u003ctd\u003ebundle value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell\/Gene\u003c\/td\u003e\n\u003ctd\u003e25%CAGR\u003c\/td\u003e\n\u003ctd\u003eminimal\u003c\/td\u003e\n\u003ctd\u003e10-15% rev\u003c\/td\u003e\n\u003ctd\u003ehigh margins\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e6.8%CAGR\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e¥3-5bn\u003c\/td\u003e\n\u003ctd\u003eneed \u0026gt;10% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMs\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;8%CAGR\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e$40-70M\/region\u003c\/td\u003e\n\u003ctd\u003e+6-10% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509029892179,"sku":"nipro-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/nipro-bcg-matrix.webp?v=1776727919","url":"https:\/\/bcgmatrixtemplate.com\/products\/nipro-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}